RO7837195

RO7837195 is an investigational small molecule drug developed by Genentech, a member of the Roche Group, currently in Phase 2 clinical trials for the treatment of moderately to severely active **ulcerative colitis** in patients who have failed prior conventional and/or advanced therapies. The drug is being studied for its efficacy, safety, and pharmacokinetics in a placebo-controlled, double-blind, multi-center trial, with both induction and extension treatment phases. Full mechanistic details and precise molecular targets have not been publicly disclosed as of June 2025; its mechanism of action remains to be announced, but it is classified as a small molecule therapy intended for immune-mediated digestive system disorders[1][2][3][4][7][9].